Redeye will likely increase its Base Case and forecasts slightly following a Q4 report coming in som...
Redeye provides its initial take on Lifco’s Q4 2023 report, which came in slightly below our estimat...
As a result of the earlier trading update, the main interest is in the outlook, especially for the U...
Hansa’s actual outcome after the trading outcome confirms that Idefirix records European product sal...
Redeye comments on Coala-Life’s latest development: the company has secured liquidity of cSEK27m thr...
We cut '24e-'25e EBITA by 9-6% Margin recovery likely to be driven by better sales mix Trading at '2...
Redeye updates its estimates and valuation following Vitec’s Q4 2023 report, featuring solid top-lin...
2023 was a weak year for the dry bulk sector, reflected in ESL Shipping's clean EBIT declining by 50...
Redeye leaves its comments on today's news that Acarix has appointed a new CEO.
Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Redeye comments on Hoylu’s Q4 2023 report, with figures missing our expectations across the board.
Redey is neutral about the return of the lipodystrophy project, as it does not affect our base case.
DT’s Q4 results were somewhat better than estimated.
SRV's net sales in Q4 amounted to EUR 181.8m, below our estimate of EUR 195.
-11% organisk tillväxt… Med volymtillväxt på ca -5% och fallande fraktpriser på 6% var den organiska...
Redeye provides its initial take on Vitec’s Q4 2023 report, which came in slightly below our estimat...
Sales +4% and adj. EBITDA -9% vs. ABGSCe Operating cash flow SEK 157m, vs ABGSCe SEK -1m Expects con...
Redeye states that sales were higher than estimated and that strong profitability led to adjusted EB...
Redeye comments on Evolution’s Q4-results which were in line with our forecast and the EBITDA-margin...
'24e-'25e EBITDA cut by 9-6% on tough macro Growth somewhat more muted on lighter investments EV/ARR...
